Recent

% | $
Quotes you view appear here for quick access.

ABIOMED, Inc. Message Board

al_the_profit 2 posts  |  Last Activity: May 20, 2015 11:19 AM Member since: Jul 5, 2006
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • al_the_profit by al_the_profit May 20, 2015 11:19 AM Flag

    I'll answer my own question,,, Rev from BEL-0222 could potentially exceed 60 Million annually,
    JUST FOR PEG-SN38 existing agreement with Hisun, We also get a piece of any new agreements
    Hisun makes..

    FROM 8K: ASSET SALE TO BELROSE

    "The aggregate upfront consideration for the assets is $800,000, $700,000 of which the Company received at closing and $100,000 of which was placed into escrow and is to be released to the Company if the Company consummates the sale of its right, title and interest in the LNA Technology platform and related assets to Belrose. The Agreement also entitles the Company to receive from Belrose additional potential payments, including a share of net revenues that may be received from Hisun related to PEG-SN38 rights in China as well as a share of other potential partnering revenues. The achievement of any of these potential payments is uncertain. "

    PEG-SN38 is very promising and in Phase III,,,

    Starman

  • al_the_profit by al_the_profit May 20, 2015 9:38 AM Flag

    Did Enzon Retain Royalty rights to the PEG phase III ready trials sold to Belrose,

    FROM the 10Q:
    "We are party to license agreements whereby we may receive royalties from products subject to
    regulatory approval"

    If Approved, BEL-0222 is expected to replace Pizer's irinotecan,,, 900 MILLION ANNUAL MARKET,,
    @7.5% ENZONS CUT would be potentially,,, 67 Million in annual Rev....

    Thanks Ahead
    Starman

ABMD
59.72-0.85(-1.40%)May 29 4:00 PMEDT